- Open Access
Gene-expression profiling of the response of peripheral blood mononuclear cells and melanoma metastases to systemic IL-2 administration
© Panelli et al., licensee BioMed Central Ltd 2002
- Received: 4 February 2002
- Accepted: 26 April 2002
- Published: 25 June 2002
lnterleukin-2 (IL-2) has direct pluripotent effects on cells with immune and inflammatory function. Which of these effects has a critical role in mediating tumor regression remains enigmatic. In this study, we compared early changes in transcriptional profiles of circulating mononuclear cells with those occurring within the microenvironment of melanoma metastases following systemic IL-2 administration.
The results suggest that the immediate effects of IL-2 administration on the tumor microenvironment is transcriptional activation of genes predominantly associated with monocyte cell function; minimal effects were noted on migration, activation and proliferation of T cells. However, production of chemokines and markers of adhesion and migration within few hours of IL-2 administration may be responsible for a secondary recruitment of immune cells to the tumor site later.
Our results suggest that IL-2 induces inflammation at tumor sites with three predominant secondary effects: activation of antigen-presenting monocytes; massive production of chemoattractants that may recruit other immune cells to the tumor (including MIG and PARC, which are specific for T cells); and activation of cytolytic mechanisms in monocytes (calgranulin, grancalcin) and NK cells (NKG5, NK4).
- Peripheral Blood Mononuclear Cell
- Tumor Microenvironment
- Human Umbilical Vein Endothelial Cell
- Peripheral Blood Mononuclear Cell Sample
- Endothelial Cell Permeability
The cytokine interleukin-2 (IL-2) has been used extensively as a single agent for immune modulation of the host in cancer therapy [1,2]. Clinical regression of metastatic melanoma and renal cell cancer resulted in long-term cures, and IL-2 has been approved by the Food and Drug Administration for standard therapy. Systemic IL-2 administration also appears to dramatically increase the frequency of tumor regression in specific immunization against cancer . It has been postulated on clinical grounds that the anti-cancer effects of IL-2 are mediated through in vivo expansion and activation of cytotoxic lymphocytes  and/or promotion of their migration within target tissues , but it has become apparent that IL-2 at the doses used therapeutically has broader immune/pro-inflammatory effects [4,5]. In addition, IL-2 may have a role in activation-induced T-cell death, therefore causing peripheral tolerance [6,7]. IL-2 administration is also associated with potent systemic toxicity that limits its therapeutic usefulness , and a relationship between toxicity and clinical effectiveness has been observed, suggesting a common effector pathway . Most peculiarly, the extent of IL-2-induced thrombocytopenia and lymphopenia is associated with increased frequency of clinical responses . Reversal of IL-2-induced toxicity by corticosteroid or anti-tumor necrosis factor-α (TNF-α) antibodies also blunts its therapeutic efficacy, further indicating the mandatory nature of this association [11,12]. The ability to distinguish the effects of IL-2 in target tissues from its systemic effects may yield important insights for the development of improved anti-cancer therapies.
With the advent of functional genomics , it has become possible to study complex biological behaviors in concert in order to obtain a panoramic view of downstream events resulting from pathophysiological alterations of entire biosystems. Thus, various aspects of the immune response can be analyzed in vitro . To our knowledge, however, little information is available about the effects of IL-2 in controlled in vitro conditions  and none about the effects of in vivo administration. We have therefore characterized the effects of IL-2 administration in vivo on the transcriptional program of circulating cells as markers of its systemic effect, and on the tumor microenvironment as a marker of its effect on target tissue.
We compared the time course of gene induction after in vitro exposure of peripheral blood mononuclear cells (PBMC) to IL-2 (6,000 IU/ml) with in vivo exposure to a dose regimen (720,000 IU/kg every 8 hours), which is associated with fairly high systemic toxicity and clinical effectiveness . The changes in expression profile induced by IL-2 in the tumor microenvironment were monitored by repeated fine-needle aspiration (FNA) biopsies. Amplified antisense RNA (aRNA) obtained from in vitro or ex vivo samples was fluorescence labeled and hybridized to 6,500-spot cDNA arrays as previously described .
Test samples consisted of gradient-separated PBMC exposed either in vitro or in vivo to IL-2, labeled with Cy5 (red) and co-hybridized with reference samples labeled with Cy3 (green). Reference samples for PBMC consisted of corresponding material for each experiment obtained before IL-2 exposure. For in vitro experiments, for example, reference samples were PBMC cultured in the absence of IL-2. For ex vivo experiments, references consisted of PBMC obtained from the respective patient before IL-2 administration. For test FNA samples obtained during the course of IL-2 administration, reference material consisted of FNA from the respective lesion obtained before IL-2 therapy. This unusual strategy was selected to emphasize the differences between pre- and post-IL-2-exposure expression profiles while minimizing differences related to individual lesion and/or patient heterogeneity. The complete data set was filtered, letting through only genes expressed at ratios > 3 or < 0.33 compared to the reference in at least one experiment. A parameter was applied to the filter that selected genes whose fluorescence intensity was above 300 in one channel at least in one experiment. This arbitrary threshold was chosen to exclude genes whose fluorescence intensity was close to background fluorescence. To recover possibly useful information, this filter was removed if the same gene demonstrated high intensity of fluorescence in the other channel (> 3,000) in at least one experiment. A total of 2,393 genes out of the 6,500 clones were selected for subsequent analyses.
Whatever the reason, the dramatic changes in the proportions of different subsets of circulating cells during IL-2 therapy introduce a strong bias into the interpretation of the in vivo data. Observed variations in gene-expression profile could be due to differential gene expression in individual cells, shifting proportions of different cell subsets, or a combination of the two. The effect of proportional shifts in cell subsets could not be overcome by ex vivo mechanical separation of these subsets because of the limited quantity of material obtained from blood draws (20 ml). However, density gradient separation of PBMC almost totally compensated for these shifts by eliminating polymorphonuclear cells, eosinophils and basophils (Figure 1c), and leaving a mononuclear cell population comparable with pre-IL-2 treatment samples. (PBMC from apheresis used as reference for in vivo studies and as source of cells for in vitro studies are highly enriched in monocytes and lymphocytes, as seen in Figure 1b.) Therefore, both in vivo and in vitro studies reflected similar starting populations of mononuclear cells. This, at least in part, mitigated the variation in gene-profile pattern due to shifting cell-subset proportions in vivo.
It has been suggested that rapid clearance of mononuclear cells after IL-2 administration is due to increased permeability of vascular endothelium , facilitating cell migration into extravascular spaces including tumor sites . However, the level of genes constitutively expressed by various subsets of mononuclear cells did not change significantly within the tumor microenvironment. Differential display of pre-compared with post-IL-2 specimens detected changes only in circulating cells (that is, of genes for CD8, CD3, CD10 and CD24; green and gray bars in Figure 1d). These most probably reflected proportional shifts in cell subsets rather than altered gene expression, because the level of expression of the same genes remained constant in the in vitro time course (data not shown). No changes could be detected in FNAs obtained pre-IL-2 administration compared with FNAs obtained 3 hours after one (light-blue bar) or four (dark-blue bar) doses. We could not confirm the aRNA-based results by immunohistochemistry because the material obtainable by FNA was not sufficient for both analyses. However, we have previously shown good correlation between transcript detection of cellular markers in aRNA, total RNA and at the protein level .
We further evaluated the effects of IL-2 on endothelial cell permeability as a possible factor mediating migration of circulating immune cells into the tumor site. IL-2 had no direct impact on the permeability of human umbilical vein endothelial cells (HUVEC) (Figure 1e). The addition of PBMC enriched in lymphocytes and monocytes by gradient separation increased the permeability of HUVEC within 3 hours. Treatment of the enriched PBMC with IL-2 (6,000 IU/ml) increased HUVEC permeability (compared to PBMC alone) only after 24 hours (Student t-test p = 0.02). This finding suggests that IL-2 affects endothelial cell permeability through activation of PBMC. The delayed effect of IL-2 on endothelial cell permeability observed with this functional assay was supported by gene profiling. IL-2 alone had minimal effects on HUVEC. Supernatant from PBMC cultures in serum-free medium had extensive effects on HUVEC transcriptional profile (data not shown). However, supernatants from PBMC conditioned for 24 hours with IL-2 (6,000 IU/ml) induced differential expression in six additional groups of genes (Figure 1f) that could not be induced with supernatants conditioned for 3 hours. These results suggest that the effect of IL-2 on endothelial cells is predominantly mediated indirectly, through activation of immune cells, and occurs at a later stage of IL-2 treatment. This conclusion is in line with the clinical observation that fluid shifts and vascular leak occur in the later phases of high-dose IL-2 therapy.
Taken together, these results suggest that immediate migration of mononuclear cells to the tumor microenvironment is not the primary effector mechanism of systemic IL-2 administration. This observation, of course, does not exclude the possibility that, at a later time, mononuclear cells might migrate or proliferate at the tumor site. The reason for the clearance of circulating cells immediately following IL-2 administration remains unsolved, and may be related to their sequestration in the reticular endothelial system, a hypothesis that could not be evaluated by this study.
Time-course analysis of IL-2-induced gene expression in PBMC in vitro
Time-course analysis of lL-2-induced gene expression in PBMC in vivo
Genes whose expression is consistently altered in peripheral blood following IL-2 administration
For some genes it was possible to extrapolate a potential cell subset responsible for their expression by testing different mononuclear cell subsets separated by negative selection after in vitro exposure to IL-2 (monocytes, CD4-+ T cells, CD8+ T cells, total lymphocytes and neutrophils, respectively, under the orange bar, Figure 4). Several were selectively expressed by either monocytes or CD4 and/or CD8 T cells. Interestingly, IL-2 also appeared to stimulate the expression of some of these genes in neutrophils, which, however, could not be accounted for in the analysis of PBMC samples enriched in monocytes and lymphocytes and almost completely depleted of neutrophils.
Genes specifically expressed in the tumor microenvironment in response to IL-2 administration
The genes whose expression was consistently altered in PBMC following IL-2 administration were analyzed in a set of FNAs obtained from the same patients plus an additional group of patients (Figure 4). Because there are practical limits on the number of FNAs that can be carried out in the same lesion without causing excessive disturbance of its structure, we sampled lesions 3 hours after one dose (first four samples in the array) and four doses (remaining six samples) of IL-2. The fourth dose (24 hours after the administration of the first) was selected as a later point likely to be reached by all patients before treatment was discontinued because of limiting toxicity . The post-IL-2 FNA material was co-hybridized with reference RNA obtained pre-IL-2 from each lesion as previously discussed. Only a small proportion of these genes were consistently upregulated in FNA samples and belonged to a closely related subcluster consisting of genes for inflammatory chemokines (MCP-1, MCP-3, IP-10, LD-78) and interferon-γ (IFN-γ)-related genes (guanylate-binding protein IFN-inducible, MxA, IP-10). Analysis of mechanically separated subsets related their expression to activation of either monocytes or T cells.
Eisen's hierarchical clustering analysis  was applied to this data set to compute relatedness among transcriptional profiles of different FNA samples. This was done to evaluate whether FNAs obtained sequentially after one or four doses of IL-2 from identical or different lesions would cluster according to time of sampling or tissue of origin. According to this data set, based on the most consistently expressed genes, samples from the same lesion clustered together independently of time, suggesting that profiles of IL-2-induced genes tend to be lesion specific throughout IL-2 therapy. The relationship among the samples independent of time of treatment was even more robust when the all-data set was queried (data not shown). Different functional subsets of genes were identified that included those for several chemokines (GRO-1, MIG, MCP-1, MCP-3, MIP1-α, MIP-β, PARC, IL-8), cytokine receptors (C-CR-1, IL-R, IL-1R antagonist, IL-2Rβ, transforming growth factor-β receptor (TGFβR), IFNγR α chain), adhesion molecules associated with mononuclear cell migration (CD62L, VCAM-1, CD64, CD29), cytotoxic proteins in granules produced by activated monocytes (grancalcin and calgranulin) and several genes associated with IFN-γ activity, such as HLA class II molecules and IFN-regulatory or responsive genes such as those for MxA, MxB and IRF-1. Interestingly, no genes associated with apoptosis or cell proliferation were identified. In addition, no evidence of migration of various immune-cell subsets was observed by analyzing changes in frequency of genes constitutively expressed by such cells (that is, CD8, CD4, CD14, and so on, see Figure 1). Thus, the early effects of IL-2 administration are more associated with an inflammatory modulation of the tumor microenvironment rather than with specific migration, activation and/or proliferation of immune cells at the tumor site.
The goal of this study was to dissect the events following administration of high-dose IL-2 for therapeutic purposes. In particular, we were interested in comparing the systemic effects of IL-2 as reflected by the transcriptional profile of circulating mononuclear cells with the effects observable within the tumor microenvironment. This was achieved by serial sampling of blood and tumor samples to follow the dynamic changes occurring during the course of IL-2 administration. The results suggest that IL-2 exerts a broad range of effects on circulating cells. These systemic effects have downstream repercussions, only a few of which were reflected in changes in gene expression at the tumor site. Analysis of the genes identified as affected by IL-2 administration suggested that IL-2 exerts its effect at the target site by causing activation of monocytes. This could be best explained by the secondary release of pro-inflammatory substances such as IFN-γ and IL-1 by circulating or intra-tumoral lymphoid cells, as most of the genes identified are known to be responsive to the effect of either of these cytokines.
A particular subset of genes whose expression appeared to be associated with a clinical response was noted. Although this observation was based on a single lesion, we were surprised to observe among them the genes for NKG5, MHC class II (which was upregulated beyond the level noted in non-responding samples) and T-cell receptor, which have all been recently associated with acute rejection of renal allografts ([23,24] and M. Sarwal, unpublished data). The phenomenon of allograft rejection and IL-2-induced tumor rejection may not only be characterized by the induction of a vigorous inflammatory response but share a common cytotoxic effector mechanism (NK/T-cell degranulation) that is ultimately responsible for direct tissue destruction. This observation agrees with the suggested synergistic role of IFN-γ and effector T cells in controlling tumor growth in experimental models . In vitro studies are presently ongoing, testing whether the changes in expression profile noted in tumor samples following IL-2 administration can be directly ascribed to the effects of IFN-γ and/or IL-1 on monocytes.
The results of this study suggest that IL-2 administration induces inflammation at the tumor site, with three predominant secondary effects: activation of antigen-presenting monocytes; a massive production of chemoattractants that may recruit other immune cells to the tumor site, among which are the chemokines MIG and PARC specific for T cells; and the activation of lytic mechanisms ascribable to monocytes (calgranulin, grancalcin) and NK cells (for example, NKG5, NK4) (Figure 8). In practical terms, these results suggest that systemic IL-2 administration may facilitate T-cell effector function in the target organ not by sustaining their proliferation, as presently believed, but rather by promoting their migration and by providing a milieu conducive to their activation in situ through activation of antigen-presenting cells. If this hypothesis is correct, then adoptive transfer of effector T cells should follow, rather than precede as at present, administration of systemic IL-2 [27,28].
Selection of patients, treatment, and sampling of PBMC and FNAs
PMBCs and FNA biopsies of melanoma metastases were obtained from patients with metastatic melanoma undergoing immunotherapy with high-dose IL-2 at the Surgery Branch, NCI (Bethesda, MD). IL-2 (720,000 IU/kg) was administered by 15 min intravenous infusion every 8 h for up to 14 consecutive doses, over 5 days, as clinically tolerated . The effect of IL-2 was analyzed in four patients' PBMC. PBMC were obtained from each patient by apheresis before IL-2 infusion and at 3 h after the fourth dose of IL-2 (patients H.P., G.P., C.P.), with the exception of one patient who was sampled twice at 3 h after the first and the second dose of IL-2 (C.P.1, C.P.3). Additionally, PBMC were obtained from one patient (C.B.) 1, 2, 3, 4, 6 and 8 h after the first dose of IL-2 (in vivo time course). Serial FNA of selected melanoma metastases were obtained from six patients (three of whom also had paired PBMC samples) before IL-2 infusion (C.F.o, G.F.o, H.F.o, K.F.o, L.F.o, M.F.o) and at 3 h after the first (C.F.1, K.F.1, l.f.1, M.F.1) and/or fourth dose of IL-2 (G.F.a4, G.F.b4, H.F.4, K.F.4, L.F.4, M.F.4). PBMC and FNA samples obtained before IL-2 administration were considered references, and those obtained after IL-2 administration were used as targets for microarray analysis
Selection of the time window and cytokine concentration for in vitrostudies
Selection of the time window and cytokine concentration for in vitro IL-2 studies was based on the pharmacokinetics of IL-2 , measuring biologically active serum IL-2 levels after administration of different doses of IL-2. Patients receiving 720,000 IU/kg IV bolus recombinant IL-2 showed a mean peak IL-2 level of 260 ± 66 ng/ml = 4,680 ± 1,188 IU/ml (18 IU = 1 ng), which then decayed with time.
To match as closely as possible the in vitro conditions with those occurring in vivo, lymphocyte/monocyte-enriched PBMC preparations were stimulated with 6,000 IU/ml IL-2 in serum-free medium.
PBMC obtained from one patient (C.B.) by apheresis before administration of IL-2 were seeded at 6 × 106 per well of a 24-well plate in OPTI-MEM medium without serum supplementation and were incubated at 37°C in the presence or absence of 6,000 IU/ml IL-2 for 0 or 5 min, or 1, 2, 3, 4, 6 and 8 h. At each time point adherent monocytes were harvested with trypsin and combined with non-adherent cells. Adherent and non-adherent cells were washed three times with PBS, differential counts were carried out by automated counting (Cell Dyn 4000, Abbott Diagnostics, Santa Clara, CA) and cells were resuspended in lysis buffer for RNA isolation (RNeasy, Qiagen, Valencia, CA). RNA was amplified using the protocol for mRNA amplification and probe preparation previously published . Each probe/test sample (antisense RNA (aRNA) obtained at each time point) was labeled with Cy5 and mixed with Cy3-labeled reference sample (non-stimulated PBMC obtained from apheresis before IL-2 administration).
Peripheral blood cells were sampled from patient C.B. during course 1, cycle 1, of high-dose IV bolus IL-2 therapy. A 10-ml blood sample was drawn at 1, 2, 3, 4, 6 and 8 h directly into a BD vacutainer™ CPT™/sodium heparin tube (BD, Franklin Lakes, NJ). Fresh blood was similarly drawn and processed from patients H.P., G.P. and C.P. at the 3-h time point during IL-2 administration. In all cases, automated differential counts were made before density-gradient separation of mononuclear cells in CPT tubes according to the manufacturer's protocol. The recovered mononuclear cells were washed three times with PBS and resuspended in lysis buffer for RNA isolation (RNeasy, Qiagen). RNA was amplified using the protocol for mRNA amplification and probe preparation according to a previously described procedure , with some additional modifications described below. Each probe/test PBMC sample was labeled with Cy5 and mixed with Cy3-labeled reference sample obtained from apheresis before IL-2 administration. FNA material was processed similarly and hybridized to microarrays using as reference sample FNA material obtained before IL-2 administration. In brief, FNA of selected metastases were carried out before and 3 h after IL-2 administration as previously described . The FNA material was immediately resuspended in ice-cold Iscove's medium without serum supplementation, and subsequently washed in PBS before RNA isolation.
Stimulation of PBMC with IL-2 and separation of single leukocyte subsets
Monocytes, CD8 and CD4 T-cell subsets were separated from patient C.B.'s PBMC (pre-IL-2 treatment) after exposure of PBMC to IL-2. In brief, 2 × 108 PBMC were thawed, washed twice in a 50:50 mixture of OPTI-MEM and Plasbumin (Bayer, West Heven, CT) and incubated for 3 h in a T175 flask in 50 ml serum-free OPTI-MEM in the presence or absence of 6,000 IU IL-2 per ml OPTI-MEM. After incubation, non-adherent cells were collected, washed in PBS, and CD4 and CD8 T-cell subsets were separated by high-affinity negative selection using CD4 and CD8 subset columns (R&D System, Minneapolis, MN) according to the manufacturer's instructions. Purified IL-2-stimulated and unstimulated CD4 and CD8 T cells were washed twice in PBS and resuspended in 350 ml RNeasy lysis buffer (Qiagen) for RNA isolation and probe preparation as previously described. The purity of the recovered T-cell subsets was assessed by FACS analysis and ranged between 79 and 83% for CD4 T cells and 89 and 90% for CD8 T cells. The remaining adherent monocytes were washed twice in PBS and simultaneously harvested and lysed for RNA isolation using 2.1 ml RNeasy lysis buffer per T175 flask, according to the manufacturer's protocol.
Direct separation of neutrophils from normal donor buffy coats
A 20-ml buffy coat suspension was overlayed onto 20 ml HESPAN (B. Broun Medical Inc, Melsunger, Germany), mixed rapidly, and incubated for 30 min at room temperature to separate red blood cells. After incubation, the supernatant was carefully removed and washed in Hanks's balanced salt solution. The cell suspension was then over-layed onto 15 ml of lymphocyte-separation medium (LSM; Organon Teknica Corp., Durham, NC) for separation of a monocyte/lymphocyte interphase and a granulocyte/red blood cell pellet. Granulocytes were separated from red blood cells by ACK lysis (Biofluids International, Rockville, MD) at 4°C for 10-15 min. Purified granulocytes were then resuspended in 700 μl RNeasy lysis buffer for probe preparation as described above. The purity of the granulocyte preparation and the neutrophil content was assessed by immunocytochemistry using DIFF quick staining according to the manufacturer's protocol (American Scientific Products, McGraw Park, IL).
Permeability was assayed using 6-well Falcon permeability chamber inserts positioned in 6-well plates (Falcon-BD Biosciences, Bedford, MA) according to the manufacturer's instructions. HUVEC were plated in the luminal chamber at 8 × 105/well/2 ml EGM-2 medium (Clonetics, San Diego, CA) on day 0 and incubated at 37°C in 5% CO2 for 48 h. On day 2, 4 × 106 PBMC/well were added on top of the HUVEC monolayer in the presence or absence of IL-2 (6,000 IU/ml) and incubated for 3 h. Control wells consisted of media supplemented with or without IL-2 in the absence of PBMC. After incubation, the content of the luminal chamber was cleared and the HUVEC monolayer was washed once with 1× Dulbecco PBS (DPBS) (Biofluids). Two milliliters of EBM-2 medium + 1% human plasma were then added to the monolayer and the cells were incubated at 37°C in 5% CO2 for 1 h. After incubation, the EBM medium was then aspirated from the luminal chamber and 1.5 ml Evans Blue dye in DPBS/0.1 BSA was added. DPBS (2 ml) was added into the abluminal (bottom) chamber followed by 1 h incubation. The insert containing the HUVEC monolayer was then discarded, and the optical density (OD) of the fluid in the abluminal chamber was measured at 620 nm using DPBS alone as blank control. Permeability was measured as increase in OD of abluminal chamber medium due to migration of Evans Blue dye from the luminal chamber. Each experimental condition was run in triplicate and repeated in three independent experiments. Changes in permeability with p < 0.01 were considered significant (Student t-test).
Differential stimulation of PBMC with IL-2 for supernatant collection
PBMC collected from apheresis before IL-2 treatment were obtained from one patient (L.B.), washed twice in a 50:50 mixture of OPTI-MEM and Plasbumin and incubated for 3 and 24 h at 1 × 108 cells/T175 flask in 50 ml serum-free OPTI-MEM in the presence or absence of 6,000 IU IL-2 per ml OPTI-MEM. After each incubation, supernatants containing non-adherent cells were collected and centrifuged twice to separate the non-adherent leukocyte populations and frozen at -30°C for stimulation of HUVEC monolayers.
Exposure of HUVEC to supernatant obtained from PBMC stimulated with IL-2
Supernatants obtained from PBMC exposed to IL-2 or OPTI-MEM (control) for 3 and 24 h were overlayed on confluent monolayers of HUVEC in T175 flasks (Falcon) at 37°C in 5% CO2 for 3 h. After incubation, 1.4-2.1 ml of RNeasy lysis buffer was added to each flask to lyse the adherent cell monolayers and isolate RNA for microarray probe preparation as described below.
Probe preparation and hybridization to microarrays
Total RNA was isolated using RNeasy minikits (Qiagen). aRNA was prepared from total RNA (0.5-3 μg) according the protocol previously described by us . In brief, two rounds of amplification were carried out, which consisted of a combination of in vitro transcription and template-switching PCR. The first round combined reverse transcription using oligo-dT (15)-T7 (5'-AAACGACGGCCAGTGAATTGTAATACGACTCACTATAGGCGC-3') primer and template-switch primer (5'-AAGCAGTGGTATCAACGCAGAGTACGCGGG-3') (Clontech, Palo Alto, CA) catalyzed by the Superscript-11 reverse transcriptase (Gibco-BRL) and Advantage cDNA polymerase (Clontech) for single- and double-strand cDNA synthesis respectively, with in vitro transcription (Megascript kit, Ambion, Austin, TX). The second round of amplification utilized 0.5 to 1 μg aRNA as starting material and resembled the first round, except for random hexamer pd(N)6 (Boehringer Mannheim, Igelheim, Germany) used in the reverse-transcription reaction in place of the template-switch primer. aRNA (3.5-5 μg) obtained after two rounds of amplification was labeled in a reverse-transcription reaction in the presence of Cy3-labeled (reference sample) or Cy5 (test sample)-labeled dUTP (Amersham, Piscataway, NJ). Test-reference sample pairs were mixed and co-hybridized to 6,500-spot microarrays.
Microarray analysis tools
Hybridized arrays were scanned at 10-μm resolution on a GenePix 4000 scanner (Axon Instruments) at variable PMT voltage to obtain maximal signal intensities with < 1% probe saturation. Resulting tiff images were analyzed via ArraySuite software (National Human Genome Research Institute, Bethesda, MD). Data was analyzed using Cluster and Tree View software by Michael Eisen .
An additional file containing the identity of the genes differentially expressed in the M.F. responding lesion after 1 (68 genes) and four doses (102 genes) of IL-2 is available.
We are grateful to David Stroncek and Joseph Even for helpful discussion. We also thank Donald White for his input on the management of array data.
- Margolin KA: Interleukin-2 in the treatment of renal cancer. Semin Oncol. 2000, 27: 194-203.PubMedGoogle Scholar
- Atkins MB, Lotze MT, Dutcher JP, Fisher RI, Weiss G, Margolin K, Abrams J, Sznol M, Parkinson DR, Hawkins M, et al: High-dose recombinant interleukin-2 therapy for patients with metastatic melanoma: analysis of 270 patients treated between 1985 and 1993. J Clin Oncol. 1999, 17: 2105-2116.PubMedGoogle Scholar
- Rosenberg SA, Yang JC, Schwartzentruber D, Hwu P, Marincola FM, Topalian SL, Restifo NP, Dufour E, Schwartzberg L, Spiess P, et al: Immunologic and therapeutic evaluation of a synthetic tumor associated peptide vaccine for the treatment of patients with metastatic melanoma. Nat Med. 1998, 4: 321-327.PubMedPubMed CentralView ArticleGoogle Scholar
- Cotran RS, Pober JS, Gimbrone MA, Springer TA, Wiebke EA, Gaspari AA, Rosenberg SA, Lotze MT: Endothelial activation during interleukin 2 immunotherapy. A possible mechanism for the vascular leak syndrome. J Immunol. 1988, 140: 1883-1888.PubMedGoogle Scholar
- Kasid A, Director EP, Rosenberg SA: Induction of endogenous cytokine-mRNA in circulating peripheral blood mononuclear cells by IL-2 administration to cancer patients. J Immunol. 1989, 143: 736-739.PubMedGoogle Scholar
- Marks-Konczalik J, Dubois S, Losi JM, Sabzevari H, Yamada N, Feigenbaum L, Waldmann TA, Tagaya Y: IL-2 induced activation-induced cell death is inhibited in IL-15 transgenic mice. Proc Natl Acad Sci USA. 2000, 97: 11445-11450. 10.1073/pnas.200363097.PubMedPubMed CentralView ArticleGoogle Scholar
- Waldmann TA, Dubois S, Tagaya Y: Contrasting roles of IL-2 and IL-15 in the life and death of lymphocytes: implications for immunotherapy. Immunity. 2001, 14: 105-110. 10.1016/S1074-7613(01)00120-0.PubMedGoogle Scholar
- Lotze MT, Matory YL, Rayner AA, Ettinghausen SE, Vetto JT, Seipp CA, Rosenberg SA: Clinical effects and toxicity of interleukin-2 in patients with cancer. Cancer. 1986, 58: 2764-2772.PubMedView ArticleGoogle Scholar
- White RLJ, Schwartzentruber D, Guleria AS, McFarlane MP, White DE, Ucker E, Rosenberg SA: Cardiopulmonary toxicity of treatment with high-dose interleukin-2 in 199 consecutive patients with metastatic melanoma or renal cell carcinoma. Cancer. 1994, 74: 3212-3222.PubMedView ArticleGoogle Scholar
- Phan GQ, Attia P, Steinberg SM, White DE, Rosenberg SA: Factors associated with response to high-dose interleukin-2 in patients with metastatic melanoma. J Clin Oncol. 2001, 19: 3477-3482.PubMedGoogle Scholar
- Papa MZ, Vetto JT, Ettinghausen SE, Mule JJ, Rosenberg SA: Effect of corticosteroid on the antitumor activity of lymphokine-activated killer cells and interleukin 2 in mice. Cancer Res. 1986, 46: 5618-5623.PubMedGoogle Scholar
- Fraker DL, Langstein HN, Norton JA: Passive immunization against tumor necrosis factor partially abrogates interleukin 2 toxicity. J Exp Med. 1989, 170: 1015-1020.PubMedView ArticleGoogle Scholar
- Brown PO, Botstein D: Exploring the new world of the genome with DNA microarrays. Nat Genet. 1999, 21: 33-37. 10.1038/4462.PubMedView ArticleGoogle Scholar
- Staudt LM, Brown PO: Genomic views of the immune system. Annu Rev Immunol. 2000, 18: 829-859. 10.1146/annurev.immunol.18.1.829.PubMedView ArticleGoogle Scholar
- Alizadeh AA, Eisen MB, Botstein D, Brown PO, Staudt LM: Probing lymphocyte biology by genomic-scale gene expression analysis. J Clin Immunol. 1998, 18: 373-379. 10.1023/A:1023293621057.PubMedView ArticleGoogle Scholar
- Rosenberg SA, Yang JC, Topalian SL, Schwartzentruber DJ, Weber JS, Parkinson DR, Seipp CA, Einhorn JH, White DE: Treatment of 283 consecutive patients with metastatic melanoma or renal cell cancer using high-dose bolus interleukin 2. JAMA. 1994, 271: 907-913. 10.1001/jama.271.12.907.PubMedView ArticleGoogle Scholar
- Wang E, Miller L, Ohnmacht GA, Liu E, Marincola FM: High fidelity mRNA amplification for gene profiling. Nat Biotechnol. 2000, 18: 457-459. 10.1038/74546.PubMedView ArticleGoogle Scholar
- Ohnmacht GA, Wang E, Mocellin S, Abati A, Filie A, Fetsch PA, Riker A, Kammula US, Rosenberg SA, Marincola FM: Short term kinetics of tumor antigen expression in response to vaccination. J Immunol. 2001, 167: 1809-1820.PubMedView ArticleGoogle Scholar
- Yang JC, Rosenberg SA: An ongoing prospective randomized comparison of interleukin-2 regimens for the treatment of metastatic renal cell cancer. Cancer J Sci Am. 1997, 3 (Suppl 1): S79-S84.PubMedGoogle Scholar
- Kammula US, White DE, Rosenberg SA: Trends in the safety of high dose bolus interleukin-2 administration in patients with metastatic cancer. Cancer. 1998, 83: 797-805. 10.1002/(SICI)1097-0142(19980815)83:4<797::AID-CNCR25>3.0.CO;2-M.PubMedView ArticleGoogle Scholar
- Eisen MB, Spellman PT, Brown PO, Botstein D: Cluster analysis and display of genome-wide expression patterns. Proc Natl Acad Sci USA. 1998, 95: 14863-14868. 10.1073/pnas.95.25.14863.PubMedPubMed CentralView ArticleGoogle Scholar
- Ross DT, Scherf U, Eisen MB, Perou CM, Rees CA, Spellman PT, Iyer V, Jeffrey SS, van de Rijn M, Waltham M, et al: Systematic variation in gene expression patterns in human cancer cell lines. Nat Genet. 2000, 24: 227-235. 10.1038/73432.PubMedView ArticleGoogle Scholar
- Sarwal MM, Jani A, Chang S, Huie P, Wang Z, Salvatierra O, Clayberger C, Sibley R, Krensky AM, Pavlakis M: Granulysin expression is a marker for acute rejection and steroid resistance in human renal transplantation. Hum Immunol. 2001, 62: 21-31. 10.1016/S0198-8859(00)00228-7.PubMedView ArticleGoogle Scholar
- Sarwal M, Chang S, Barry C, Alizadeh AA, Salvatierra O, Brown PO: Genomic analysis of renal allograft dysfunction using cDNA microarrays. Transplant Proc. 2001, 33: 297-298. 10.1016/S0041-1345(01)01917-0.PubMedView ArticleGoogle Scholar
- Shankaran V, Ikeda H, Bruce AT, White JM, Swanson PE, Old LJ, Schreiber RD: IFN-γ and lymphocytes prevent primary tumour development and shape tumour immunogenicity. Nature. 2001, 410: 1107-1111. 10.1038/35074122.PubMedView ArticleGoogle Scholar
- Albert ML, Jegathesan M, Darnell B: Dendritic cell maturation is required for the cross-tolerization of CD8+ T cells. Nature Immunol. 2001, 2: 1010-1016. 10.1038/ni722.View ArticleGoogle Scholar
- Rosenberg SA, Lotze MT, Muul LM, Leitman S, Chang AE, Ettinghausen SE, Matory YL, Skibber JM, Shiloni E, Vetto JT, et al: Observations on the systemic administration of autologous lymphokine-activated killer cells and recombinant interleukin-2 to patients with metastatic cancer. N Engl J Med. 1985, 313: 1485-1492.PubMedView ArticleGoogle Scholar
- Rosenberg SA, Yannelli JR, Yang JC, Topalian SL, Schwartzentruber DJ, Weber JS, Parkinson DR, Seipp CA, Einhorn JH, White DE: Treatment of patients with metastatic melanoma with autologous tumor-infiltrating lymphocytes and interleukin 2. J Natl Cancer Inst. 1994, 86: 1159-1166. 10.1093/jnci/86.15.1159.PubMedView ArticleGoogle Scholar
- Rosenberg SA: Interleukin-2 and the development of immunotherapy for the treatment of patients with cancer. Cancer J Sci Am. 2000, 6: S2-S7.PubMedGoogle Scholar
- Panelli MC, Riker A, Kammula US, Lee K-H, Wang E, Rosenberg SA, Marincola FM: Expansion of tumor/T cell pairs from fine needle aspirates (FNA) of melanoma metastases. J Immunol. 2000, 164: 495-504.PubMedView ArticleGoogle Scholar